Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 8/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.45 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14511752 | 0.94 | SLC6A4 (0.52) | CCR5LMNASLC6A4PTGER1CYP1A2 | |
| SCHEMBL1107091 | 0.86 | PTGER1 (0.45) | CCR5LMNAPTGER1HTTSMN1; SMN2 | |
| SCHEMBL30008548 | 0.82 | MEN1 (0.44) | LMNACYP1A2ALDH1A1RAB9A | |
| SCHEMBL31644088 | 0.82 | SLC6A4 (0.66) | CCR5LMNASLC6A4PTGER1ALDH1A1 | |
| SCHEMBL368071 | 0.82 | SLC6A4 (0.66) | CCR5LMNASLC6A4PTGER1ALDH1A1 | |
| SCHEMBL6451525 | 0.82 | LIPE (0.47) | CCR5LMNAPTGER1CYP1A2ALDH1A1 | |
| SCHEMBL14511787 | 0.81 | PTGER1 (0.45) | CCR5LMNAPTGER1ALDH1A1HTT | |
| SCHEMBL7073094 | 0.80 | MEN1 (0.45) | LMNAALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL2901054 | 0.80 | MAOB (0.47) | LMNACYP1A2RAB9ASMN1; SMN2MAOB | |
| SCHEMBL2060462 | 0.79 | SMPD1 (0.59) | CCR5LMNASLC6A4ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014767-A1 | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases | INCYTE CORPORATION | 2005-01-20 | — | — | US | disclosed |
| WO-2004066952-A2 | BENZOXAZOLE, BENZOTHIAZOLE, AND BENZIMIDAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER DISEASES | INCYTE CORPORATION (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014767-A1 | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases | AR, CCNT1, BRD1 | CCR5 4565/4885LMNA 3177/4885SLC6A4 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.